Heterocyclic sulfonamide inhibitors of beta amyloid production

Details Heterocyclic sulfonamide inhibitors of beta amyloid production Heterocyclic sulfonamide inhibitors of beta amyloid production

2009-10-09

2010-11-30

Kosack, Joseph R (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C549S065000

Reexamination Certificate

active

07842718

ABSTRACT:
Compounds of Formula (I),wherein R1, R2, R3, R4, R5, R6, T, W, X, Y and Z are as defined herein are provided, together with pharmaceutically acceptable salt, hydrates and/or prodrugs thereof. Methods of using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's disease and Down's syndrome are described.

REFERENCES:
patent: 5464853 (1995-11-01), Chan et al.
patent: 5506243 (1996-04-01), Ando
patent: 5514691 (1996-05-01), Chan et al.
patent: 5561146 (1996-10-01), Kim
patent: 5571821 (1996-11-01), Chan
patent: 5591761 (1997-01-01), Chan et al.
patent: 5593846 (1997-01-01), Schenk
patent: 5594021 (1997-01-01), Chan
patent: 5624937 (1997-04-01), Reel
patent: 5703129 (1997-12-01), Felsenstein
patent: 5710153 (1998-01-01), Ohmoto
patent: 5852007 (1998-12-01), Chatterjee
patent: 5877193 (1999-03-01), Cesura
patent: 5981168 (1999-11-01), Reiner
patent: 6248775 (2001-06-01), Vazquez
patent: 6342610 (2002-01-01), Chan
patent: 6376523 (2002-04-01), Chan
patent: 6566536 (2003-05-01), Muller
patent: 6610734 (2003-08-01), Kreft et al.
patent: 6657070 (2003-12-01), Resnick
patent: 6878742 (2005-04-01), Kreft
patent: 7166622 (2007-01-01), Kreft
patent: 7300951 (2007-11-01), Kreft
patent: 7547725 (2009-06-01), Kreft
patent: 2009/0227667 (2009-09-01), Kreft
patent: 510700 (1992-10-01), None
patent: 0 652 009 (1995-05-01), None
patent: 652009 (1995-05-01), None
patent: 1172361 (1999-12-01), None
patent: 1088821 (2001-04-01), None
patent: 5-148233 (1993-06-01), None
patent: 07-048340 (1995-02-01), None
patent: 08-053492 (1996-02-01), None
patent: 09-136878 (1997-05-01), None
patent: 09-235276 (1997-09-01), None
patent: 10-067761 (1998-03-01), None
patent: 11-343279 (2002-01-01), None
patent: WO-95/29904 (1995-11-01), None
patent: WO-97/21690 (1997-06-01), None
patent: WO-97/24340 (1997-07-01), None
patent: WO-98/03166 (1998-01-01), None
patent: WO-98/16504 (1998-04-01), None
patent: WO-98/22104 (1998-05-01), None
patent: WO-98/22493 (1998-05-01), None
patent: WO-99/28316 (1999-06-01), None
patent: WO-99/62880 (1999-12-01), None
patent: WO-00/09107 (2000-02-01), None
patent: WO-00/50391 (2000-08-01), None
patent: WO-01/23379 (2001-04-01), None
patent: WO-01/27091 (2001-04-01), None
patent: WO-01/27108 (2001-04-01), None
patent: WO-02/057252 (2002-07-01), None
patent: WO-03/050062 (2003-06-01), None
patent: WO-03/050063 (2003-06-01), None
patent: WO-03/103660 (2003-12-01), None
Abstract of Japanese Patent No. JP-11-343279 Jan. 26, 2002.
Augelli-Szafran, “β-amyloid as a target for Alzheimer's Disease therapy”, Annual Reports in Medicinal Chemistry Ch. 3, Aug. 30, 1999 (34):21-30.
Dodart, “The β-amyloid precursor protein and its derivatives: From biology to learning and memory process”, Reviews in the Neurosciences 2000 11(2-3):75-93.
Esler, “Transition-state analogue inhibitors of β-secretase bind directly to presenilin-1”, Nature Cell Bio. Jul. 2000 2:428-434.
Findeis, “Modified-peptide inhibitors of amyloid β-peptide polymerization”, Biochem. May 25, 1999 38(21):6791-6800.
Ghosh, “Design of potent inhibitors for human brain memapsin 2 (β-secretase)”, J. Am. Chem. Soc., Apr. 12, 2000 122:3522-3523.
Goate, A., “Monogenetic determinants of Alzheimer's Disease: APP mutations”, Cell. Mol. Life Sci. Sep. 1998 54:897-901.
Han, “Total asymmetric synthesis of highly constrained amino acids isopropyl-2′, 6′-dimethyl-tyrosines”, Tetrahedron Letters, Jul. 21, 1997 38(29):5135-5138.
John, “Chapter 2. Alzheimer's Disease: Recent advances on the amyloid hypothesis”, Ann. Reports Med. Chem., Sep. 1997 32:11-20.
Larner, “Review—Central and peripheral nervous systems—Alzheimer's disease: Towards therapeutic manipulation of the amyloid precursor protein and amyloid peptides”, Exp. Opin. Ther. Patents, Oct. 1997 7(10):1115-1127.
Li, “Photoactivated β-secretase inhibitors directed to the active site covalently label presenilin 1”, Nature Jun. 2000 405:689-694.
Li, “The amyloid precursor protein of Alzheimer's Disease in human brain and blood”, J. of Leuko. Bio. Oct. 1999 66:567-574.
Moore, “Inhibition of β-amyloid formation as a therapeutic strategy”, Exp. Opin. Ther. Patents, Moore 1999 9(2):135-146.
Naslund, “Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline”, Jama, Mar. 2000, 283(12):1571-1577.
Rishton, “Fenchylamine sulfonamide inhibitors of amyloid peptide production by the β-secretase proteolytic pathway: potential small-molecule therapeutic agents for the treatment of Alzheimer's Disease”, J. Med. Chem., Jun. 15, 2000, 43(12):2297-2299.
Sabbagh, “β-amyloid and treatment opportunities for Alzheimer's Disease”, Alzheimer's Disease Review 1997 3:1-19.
Sinha, “Purification and cloning of amyloid precursor protein β-secretase from human brain”, Nature Dec. 1999 402:537-540.
Skovronsky, “β-secretase revealed: Starting gate for race to novel therapies for Alzheimer's Disease”, TIPS May 2000 21:161-163.
Small, “Alzheimer's Disease and the amyloid protein: What is the role of amyloid?”, J. Neurochem. Aug. 1999 73(2):443-449.
Testa, “Prodrugs revisited: The “Ad Hoc” approach as a complement to ligand design”, Med. Res. Rev. May 1996 16(3):233-241.
Wagner, “Modulation of amyloid protein precursor processing as a means of retarding progression of Alzheimer's Disease”, J. Clin. Invest. Nov. 1999 104(10):1329-1332.
Wermuth, “Molecular variations based on isosteric replacements”, Prac. Med. Chem. Feb. 1996, pp. 203-237.
Wolfe, “A substrate-based difluoro ketone selectively inhibits Alzheimer's β-secretase activity”, J. Med. Chem. Jan. 1, 1998 41:6-9.
Mehta, “Techniques in Diagnostic Pathology”, vol. 2, Bullock et al., Eds., Academic Press: Boston, MA, 1991, pp. 99-112.
Office Action dated May 24, 2004 issued in U.S. Appl. No. 10/455,674.
Response to Office Action dated May 24, 2004 issued in U.S. Appl. No. 10/455,674.
Office Action dated Jun. 2, 2009 issued in U.S. Appl. No. 11/081,784.
Response to Office Action dated Jun. 2, 2009 issued in U.S. Appl. No. 11/081,784.
Office Action dated Dec. 1, 2008 issued in U.S. Appl. No. 11/081,784.
Response to Office Action dated Dec. 1, 2008 issued in U.S. Appl. No. 11/081,784.
Office Action dated Mar. 7, 2008 issued in U.S. Appl. No. 11/081,784.
Response to Office Action dated Mar. 7, 2008 issued in U.S. Appl. No. 11/081,784.
Office Action dated Jun. 13, 2007 issued in U.S. Appl. No. 11/081,784.
Response to Office Action dated Jun. 13, 2007 issued in U.S. Appl. No. 11/081,784.
Sugihara, English Abstract of JP 09-235276 (Sep. 9, 1997).
Cesura and Rover, English Abstract of JP 10-067761 (Mar. 10, 1998).
Omoto, English Abstract of JP 09-136878 (May 27, 1997).
Kim, English Abstract of JP 08-053492 (Feb. 27, 1996).
Ando, English Abstract of JP 07-048340 (Feb. 21, 1995).
Office Action issued in related Singapore Patent Application No. 200503628-0 (Oct. 3, 2008).
Office Action issued in corresponding Japanese Patent Application No. 557933/02 (Jun. 10, 2008).
International Search Report issued in International Patent Application No. PCT/US01/48375 (Aug. 2, 2002).
International Search Report issued in International Patent Application No. PCT/US03/18198 (Nov. 3, 2003).
International Search Report issued in International Patent Application No. PCT/US2004/009268 (Aug. 13, 2004).

Affiliated with

Also associated with

Rating

Heterocyclic sulfonamide inhibitors of beta amyloid production does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic sulfonamide inhibitors of beta amyloid production, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic sulfonamide inhibitors of beta amyloid production will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4246035